BB Biotech returns to TecDAX

Friday, 07. September 2012 09:18

BB Biotech AG / BB Biotech returns to TecDAX . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Change in the composition of the technology index (TecDAX) in Frankfurt: The Deutsche Börse has announced that BB Biotech will be added to the TecDAX on September 24 after a brief three-month period of non-membership. The biotech investment company meets all criteria for inclusion in the TecDAX.

With a market value of almost one billion euros, the Swiss investment company BB Biotech (ISIN CH0038389992) has long been a member of the TecDAX. It was briefly removed from the TecDAX in June of this year because of the requirement that at least one-third of the trading turnover in a foreign company's stock must be conducted on the Frankfurt stock exchange and the Xetra trading platform in order to be included in the TecDAX. After three short months BB Biotech was again able to meet this criterion.

BB Biotech will rejoin the TecDAX technology index on September 24, 2012. "We are very pleased to be part of the index again. The German market is important for BB Biotech and being a member of the TecDAX underscores both the significance of our company and the good performance of the biotech sector during past years," says Dr. Daniel Koller, the head of BB Biotech's portfolio management team. BB Biotech's Net Asset Value increased by 39.2% (in USD), 40.6% (in CHF) and 42.2% (in EUR) during the first half of 2012.

The German TecDAX technology index tracks the 30 largest technology stocks as measured by market capitalization and trading turnover that are not part of the blue-chip DAX index. The selection of TecDAX stocks and their weightings are reviewed every six months in March and September and adjusted when necessary.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, telephone +41 44 267 67 09,

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with around CHF 1.2 bn in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: BB Biotech AG via Thomson Reuters ONE


--- End of Message ---

BB Biotech AG
Vordergasse 3 Schaffhausen Switzerland

WKN: 888509;ISIN: CH0038389992;Index:TecDAX,MIDCAP,Prime All Share,TECH All Share,HDAX;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse;

Related Links: BB Biotech AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.